The End of Back Pain? Sometimes It’s All In The Head – So Is The Treatment

We all know some people who fake back pain but, as a onetime sufferer myself I know it can be excruciating and very real if sometimes difficult for doctors to diagnose and very difficult to treat. Recent studies show that a back injury can alter brain structure and that an existing drug (not a pain reliever) can help.

Doctors know that many people complaining of back pain are really suffering even though no real cause can be found on x-rays – even worse, the usual battery of pain relievers from NSAIDs to mild narcotics don’t offer much relief.

The BackCare Journal states, “The overarching message that arises from the clinical trials of treatments for chronic low back pain is that current interventions provide only small short term benefits when compared to sham treatment or no treatment.”

http://www.backcare.org.uk/779-6681/The-brain-in-chronic-low-back-pain.html

But there is new hope and a powerful one. The Journal of Neuroscience, vol 26, p 12165 carries a report by A. V. Apkarian, Dept. of Physiology, Northwestern U. School of Medicine which explains that chronic back pain can lead to changes in the brain making the individual more sensitive to the pain. “”The brain is reorganising in these patients. It amplifies the pain signal.”

The important implications include the discovery that low doses cycloserine, an antibiotic used to treat tuberculosis (mycobacterium or MAP infections), dampens activity in that part of the brain in rats.

http://en.wikipedia.org/wiki/Cycloserine

Human clinical trials are beginning soon, but those can take a decade or longer and, since this is an existing drug and the effective dose for reducing back pain is one-fifth the safe dose for treating TB, some patients may wish to let their doctor know about these results and try treatment called off-label, which is perfectly legal and only means using an existing drug to treat something it wasn’t originally developed to treat.

All drugs have side-effects, but one which many people are already taking in higher doses are more likely to be safe than a new drug, especially in treating pain which isn’t effectively managed by analgesics.

Chronic pain which can’t be managed using analgesics is of particular concern because people are prone to taking larger doses of dangerous pain killers in an attempt to get relief.

Although people in great pain can tolerate narcotic doses which are normally fatal – when the narcotics work, I know of no studies showing whether this is also true when the narcotics don’t provide any real relief which is sometimes the case with chronic back pain. Knowing that the pain can cause physical alterations in the brain explains why narcotics, which act by blocking certain chemical signals in the brain, aren’t effective in those cases.

Hot this week

Did David Wineland and Serge Haroche Steal Idea For The Nobel Physics Prize?

Dr. Omerbashich says the Royal Swedish Academy is a Crime Scene and he has the proof that Nobel laureates stole his discovery.

New Approaches to Disaster Relief Challenges

Disaster relief has always been a challenge. NASA, Google,...

3 Legitimate Money Making Methods to Supplement Your Income

In a perfect world, when your landlord raises your...

2016 Predictions by World Renowned Medium and Psychic Lindy Baker

World renowned medium and psychic Lindy Baker is interviewed by The Hollywood Sentinel, discussing psychic power, the spirit world, life after death, areas of concern in 2016, and much more.

Digital Coupon Customers Spending More Than Double At Stores

A new study shows that customers who use digital coupons go shopping more for groceries and other household goods more often and spend more on their shopping trips.

Type 1 Diabetic Built Sugar Sense So His Glucose Reading Would Follow Him Everywhere

Kurtanidze, founder of Sugar Sense and a Type 1 diabetic for more than 12 years, spends much of his working day at a computer.

Tommy Shields and Onyx Reserve: Building at the Intersection of Real Estate, Sports and Culture

Citadel's $2.5bn Brickell tower and a $117m arena naming deal sit inside the same twenty-minute drive, and get written about by different reporters in different sections. Tommy Shields, Head of Investor Relations at Onyx Reserve, on why they are the same story.

Comparing Countertop Materials: Which Is Best for You?

Remodeling your cooking space is an exciting project, but...

Tips for Interacting with Horses

There’s something incredibly special about spending time with horses....

Breaking Down Your Printer So It Doesn’t Break Down On You

Nothing stops a productive morning faster than a flashing...

Why You Should Always Book Your Accessible Ride Ahead of Time

Getting from point A to point B should be...

Spotting the Gaps: Common Construction Bid Discrepancies and How to Avoid Them

Putting together a winning construction bid takes time, precision,...

Related Articles

Popular Categories